Biosplice Therapeutics
Restoring health through first-in-class therapies harnessing alternative splicing
- Headquarters
- San Diego, California
- Employees
- 51–200
- Founded
- 2008
- Business Model
- B2B
- Website
- biosplice.com
- Total Funding
- $120.0M
- Last Round
- $120.0M Series BApr 2021
- Rounds
- 1
About
Biosplice Therapeutics is a clinical-stage biopharmaceutical company pioneering therapeutic modulation of alternative pre-mRNA splicing. Founded in 2008 and based in San Diego, California, Biosplice's platform targets the CLK/DYRK family kinases that govern tissue-specific RNA splice-site selection. Its lead program, lorecivivint (LOR), a CLK2/DYRK1A inhibitor, has submitted a New Drug Application to the FDA for knee osteoarthritis treatment — potentially the first approved osteoarthritis drug in two decades. The company also has programs in Alzheimer's disease and oncology.
Tech & App Stack
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingSign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Apr 2021
Investors
Sign up to view investors
Create a free account to see which investors have funded this company.
Create Free AccountSimilar Companies
Biopharmaceutical services company
Specialty pharmaceutical company
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...